Literature DB >> 19427740

Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.

Neal E Dunlap1, Jing Cai, Gregory B Biedermann, Wensha Yang, Stanley H Benedict, Ke Sheng, Tracey E Schefter, Brian D Kavanagh, James M Larner.   

Abstract

PURPOSE: To identify the dose-volume parameters that predict the risk of chest wall (CW) pain and/or rib fracture after lung stereotactic body radiotherapy. METHODS AND MATERIALS: From a combined, larger multi-institution experience, 60 consecutive patients treated with three to five fractions of stereotactic body radiotherapy for primary or metastatic peripheral lung lesions were reviewed. CW pain was assessed using the Common Toxicity Criteria for pain. Peripheral lung lesions were defined as those located within 2.5 cm of the CW. A minimal point dose of 20 Gy to the CW was required. The CW volume receiving >or=20, >or=30, >or=40, >or=50, and >or=60 Gy was determined and related to the risk of CW toxicity.
RESULTS: Of the 60 patients, 17 experienced Grade 3 CW pain and five rib fractures. The median interval to the onset of severe pain and/or fracture was 7.1 months. The risk of CW toxicity was fitted to the median effective concentration dose-response model. The CW volume receiving 30 Gy best predicted the risk of severe CW pain and/or rib fracture (R(2) = 0.9552). A volume threshold of 30 cm(3) was observed before severe pain and/or rib fracture was reported. A 30% risk of developing severe CW toxicity correlated with a CW volume of 35 cm(3) receiving 30 Gy.
CONCLUSION: The development of CW toxicity is clinically relevant, and the CW should be considered an organ at risk in treatment planning. The CW volume receiving 30 Gy in three to five fractions should be limited to <30 cm(3), if possible, to reduce the risk of toxicity without compromising tumor coverage. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19427740     DOI: 10.1016/j.ijrobp.2009.02.027

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  91 in total

Review 1.  The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient?

Authors:  Gregory M M Videtic; Kevin L Stephans
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

Review 2.  Rationale for ablation of oligometastatic disease and the role of stereotactic body radiation therapy for hepatic metastases.

Authors:  Chad G Rusthoven; Tracey E Schefter
Journal:  Hepat Oncol       Date:  2013-12-20

3.  Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation.

Authors:  Patrick Kelly; Peter A Balter; Neal Rebueno; Hadley J Sharp; Zhongxing Liao; Ritsuko Komaki; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-08       Impact factor: 7.038

Review 4.  Alternatives to surgery for early stage non-small cell lung cancer-ready for prime time?

Authors:  Millie Das; Mohamed H K Abdelmaksoud; Billy W Loo; Nishita Kothary
Journal:  Curr Treat Options Oncol       Date:  2010-06

5.  Characterization of Chest Wall Toxicity During Long-term Follow Up After Thoracic Stereotactic Body Radiation Therapy.

Authors:  Christopher Chipko; Julius Ojwang; Leila Rezai Gharai; Xiaoyan Deng; Nitai Mukhopadhyay; Elisabeth Weiss
Journal:  Pract Radiat Oncol       Date:  2019-02-04

6.  Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment.

Authors:  Jeremy M Kilburn; Jeffrey G Kuremsky; A William Blackstock; Michael T Munley; William T Kearns; William H Hinson; James F Lovato; Antonius A Miller; William J Petty; James J Urbanic
Journal:  Radiother Oncol       Date:  2014-01-17       Impact factor: 6.280

7.  End-of-Range Radiobiological Effect on Rib Fractures in Patients Receiving Proton Therapy for Breast Cancer.

Authors:  Chia-Chun Wang; Aimee L McNamara; Jungwook Shin; Jan Schuemann; Clemens Grassberger; Alphonse G Taghian; Rachel B Jimenez; Shannon M MacDonald; Harald Paganetti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-03-30       Impact factor: 7.038

8.  Non-surgical management of stage I lung cancer.

Authors:  Elizabeth M Gore
Journal:  F1000 Med Rep       Date:  2010-03-25

9.  Myositis following spine radiosurgery for metastatic disease: a case series.

Authors:  Dennis T Lockney; Angela Y Jia; Eric Lis; Natalie A Lockney; Chengbao Liu; Benjamin Hopkins; Daniel S Higginson; Yoshiya Yamada; Ilya Laufer; Mark Bilsky; Adam M Schmitt
Journal:  J Neurosurg Spine       Date:  2018-01-26

10.  Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced Chest Wall Pain.

Authors:  Shaun U Din; Eric L Williams; Andrew Jackson; Kenneth E Rosenzweig; Abraham J Wu; Amanda Foster; Ellen D Yorke; Andreas Rimner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-06-14       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.